Top Markets
#1 Helium Helium +51.12%
#2 TENDIES TENDIES +40.50%
#3 Pons Pons +28.45%
#4 Seeker Seeker +20.84%
#5 UnifAI Network UnifAI Network +19.25%
#6 Songbird Songbird +12.26%
#7 Lista DAO Lista DAO +11.34%
#8 OSK OSK +10.10%
#9 DAPPOS DAPPOS +9.96%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +9.71%
Coin of the day
Helium Helium
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Climb Bio, Inc. Climb Bio, Inc.

Climb Bio, Inc.

CLYM
Clasificación en acciones #10440
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic... Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Precio por acción
$14.66
Última sincronización: 2026-08-28
Capitalización bursátil
$839.37M
Cambio (1 día)
-2.67%
Cambio (1 año)
557.32%
País
US
Comercio Climb Bio, Inc. (CLYM)

Categoría

Healthcare
Ganancias de Climb Bio, Inc. (CLYM)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Climb Bio, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Climb Bio, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH